Chronic disease diagnosis and treatment company SonmolTech completes multi-million-yuan strategic financing

The chronic disease diagnosis and treatment company SonmolTech has received tens of millions of yuan in strategic financing. This round of financing was invested by Aptar, a packaging solutions provider in the medical and consumer industries. Lanchi Ventures is the investor for Series A round of SonmolTech.

The chronic disease diagnosis and treatment company SonmolTech has received tens of millions of yuan in strategic financing. This round of financing was invested by Aptar, a packaging solutions provider in the medical and consumer industries. Lanchi Ventures is the investor for Series A round of SonmolTech.

The proceeds will be used to promote and commercialize SonmolTech’s core product, the disease diagnosis and treatment management system, establish deeper cooperation with hospitals and explore business models, and increase the strength of talent recruitment in the meantime.

As a strategic investor, Aptar will cooperate with SonmolTech in the fields of digital disease management platforms and algorithms, and accelerate the development, manufacturing, commercialization and supply of respiratory medicines that have been marketed or under development to realize digitization of drug delivery, diagnosis and patient support.

SonmolTech was established in 2015, and its core team members are mostly from multinational pharmaceutical companies, well-known internet companies, 3A-level hospitals, scientific research institutions and others.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/24/chronic-disease-diagnosis-and-treatment-company-sonmoltech-completes-multi-million-yuan-strategic-financing/.

Leave a Reply

Please Login to Comment